Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163405 | 0.86 | ALDH1A1 (0.44) | RPS6KA2MAPTALDH1A1GAAKMT2A | |
| SCHEMBL2064760 | 0.84 | MAPT (0.57) | RPS6KA2MAPTALDH1A1GAAKMT2A | |
| SCHEMBL4155501 | 0.78 | MEN1 (0.46) | MAPTALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL565366 | 0.77 | ALDH1A1 (0.64) | MAPTALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL416817 | 0.77 | APP (0.47) | RPS6KA2MAPTALDH1A1GAAKMT2A | |
| SCHEMBL2089878 | 0.75 | MAPT (0.42) | RPS6KA2MAPTALDH1A1GAAKMT2A | |
| SCHEMBL1950296 | 0.75 | MAPT (0.42) | RPS6KA2MAPTALDH1A1GAAKMT2A | |
| SCHEMBL11516786 | 0.75 | IDO1 (0.44) | RPS6KA2MAPTALDH1A1GAAKMT2A | |
| SCHEMBL295193 | 0.75 | KCNH3 (0.54) | RPS6KA2MAPTALDH1A1GAAKMT2A | |
| SCHEMBL5074435 | 0.75 | MAPT (0.42) | RPS6KA2MAPTALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | RPS6KA2 1727/4885MAPT 2739/4885ALDH1A1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.